PURPOSE: Low physical functioning among breast cancer survivors appears to reduce survival, although the mechanisms underlying these associations are not clear. We examined inflammation as a possible biological mediator of association between low physical functioning and mortality after breast cancer. METHODS: Analysis included 2,892 participants from the Women's Healthy Eating and Living Study. All measures were collected at study baseline. Physical function was assessed by the Short Form 36 (SF-36) Health Survey Physical Function subscale. Low physical function was defined as the bottom tertile of the subscale score. Inflammation was measured as serum concentration of C-reactive protein (CRP). Cox proportional hazards modeled the associations of low physical function and the putative mediator (i.e., CRP) with all-cause and breast cancer-specific mortality. RESULTS: There were 293 deaths during study follow up, with 243 due to breast cancer. Low physical functioning was associated with a 50 % higher risk of all-cause mortality (HR, 1.49; 95 % CI, 1.2-1.9) and a 40 % higher risk of breast cancer-specific mortality (HR, 1.39; 95 % CI, 1.1-1.8), after adjustment for covariates. The addition of CRP did not markedly change the all-cause mortality hazard ratio attributed to low physical functioning. However, the addition of CRP modestly attenuated the breast cancer-specific mortality hazard ratio such that it was no longer statistically significant. CONCLUSIONS: Interventions to improve physical functioning may prevent early morbidity and mortality among breast cancer survivors. IMPLICATIONS FOR CANCER SURVIVORS: Functional status measure may be a valuable indicator of long-term health outcomes among breast cancer survivors.
PURPOSE: Low physical functioning among breast cancer survivors appears to reduce survival, although the mechanisms underlying these associations are not clear. We examined inflammation as a possible biological mediator of association between low physical functioning and mortality after breast cancer. METHODS: Analysis included 2,892 participants from the Women's Healthy Eating and Living Study. All measures were collected at study baseline. Physical function was assessed by the Short Form 36 (SF-36) Health Survey Physical Function subscale. Low physical function was defined as the bottom tertile of the subscale score. Inflammation was measured as serum concentration of C-reactive protein (CRP). Cox proportional hazards modeled the associations of low physical function and the putative mediator (i.e., CRP) with all-cause and breast cancer-specific mortality. RESULTS: There were 293 deaths during study follow up, with 243 due to breast cancer. Low physical functioning was associated with a 50 % higher risk of all-cause mortality (HR, 1.49; 95 % CI, 1.2-1.9) and a 40 % higher risk of breast cancer-specific mortality (HR, 1.39; 95 % CI, 1.1-1.8), after adjustment for covariates. The addition of CRP did not markedly change the all-cause mortality hazard ratio attributed to low physical functioning. However, the addition of CRP modestly attenuated the breast cancer-specific mortality hazard ratio such that it was no longer statistically significant. CONCLUSIONS: Interventions to improve physical functioning may prevent early morbidity and mortality among breast cancer survivors. IMPLICATIONS FOR CANCER SURVIVORS: Functional status measure may be a valuable indicator of long-term health outcomes among breast cancer survivors.
Authors: K Nakajima; M Takeoka; M Mori; S Hashimoto; A Sakurai; H Nose; K Higuchi; N Itano; M Shiohara; T Oh; S Taniguchi Journal: Int J Sports Med Date: 2010-03-03 Impact factor: 3.118
Authors: Anne McTiernan; Charles Kooperberg; Emily White; Sara Wilcox; Ralph Coates; Lucile L Adams-Campbell; Nancy Woods; Judith Ockene Journal: JAMA Date: 2003-09-10 Impact factor: 56.272
Authors: Brandon L Pierce; Marian L Neuhouser; Mark H Wener; Leslie Bernstein; Richard N Baumgartner; Rachel Ballard-Barbash; Frank D Gilliland; Kathy B Baumgartner; Bess Sorensen; Anne McTiernan; Cornelia M Ulrich Journal: Breast Cancer Res Treat Date: 2008-04-10 Impact factor: 4.872
Authors: Patricia A Ganz; Lorna Kwan; Annette L Stanton; Janice L Krupnick; Julia H Rowland; Beth E Meyerowitz; Julienne E Bower; Thomas R Belin Journal: J Natl Cancer Inst Date: 2004-03-03 Impact factor: 13.506
Authors: Roberta De Angelis; Andrea Tavilla; Arduino Verdecchia; Steve Scoppa; Mark Hachey; Eric J Feuer; Angela B Mariotto Journal: Cancer Date: 2009-05-01 Impact factor: 6.860
Authors: John P Pierce; Susan Faerber; Fred A Wright; Cheryl L Rock; Vicky Newman; Shirley W Flatt; Sheila Kealey; Vicky E Jones; Bette J Caan; Ellen B Gold; Mary Haan; Kathryn A Hollenbach; Lovell Jones; James R Marshall; Cheryl Ritenbaugh; Marcia L Stefanick; Cynthia Thomson; Linda Wasserman; Loki Natarajan; Ronald G Thomas; Elizabeth A Gilpin Journal: Control Clin Trials Date: 2002-12
Authors: Arti Hurria; Enrique Soto-Perez-de-Celis; Jacob B Allred; Harvey Jay Cohen; Anait Arsenyan; Karla Ballman; Jennifer Le-Rademacher; Aminah Jatoi; Julie Filo; Jeanne Mandelblatt; Jacqueline M Lafky; Gretchen Kimmick; Heidi D Klepin; Rachel A Freedman; Harold Burstein; Julie Gralow; Antonio C Wolff; Gustav Magrinat; Myra Barginear; Hyman Muss Journal: J Am Geriatr Soc Date: 2018-08-26 Impact factor: 5.562
Authors: Chandler Coleman; Connie H Yan; Naomi Y Ko; Nadia A Nabulsi; Kent F Hoskins; Brian C-H Chiu; Gregory S Calip Journal: Breast Date: 2022-04-14 Impact factor: 4.254
Authors: Arielle S Radin; Julienne E Bower; Michael R Irwin; Arash Asher; Sara A Hurvitz; Steve W Cole; Catherine M Crespi; Patricia A Ganz Journal: NPJ Breast Cancer Date: 2022-08-08